FDA Approves Pfizer's Talzenna Combo; Prostate Cancer Use Hinges on Gene Test

The efficacy case rests on TALAPRO-3, a randomized, double-blind, placebo-controlled trial that enrolled 599 patients with HRR gene-mutated mAPMN/S prostate cancer. Participants were assigned 1:1 to enzalutamide plus either talazoparib or placebo daily, and every patient also received continuous androgen deprivation therapy. Mutation status was determined prospectively using tumor tissue or circulating tumor DNA-based next-generation sequencing across 12 genes: ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2 and RAD51C.

The primary endpoint was radiographic progression-free survival, measured by investigator assessment under RECIST version 1.1 and PCWG3 bone criteria. Median rPFS was not reached in the talazoparib-plus-enzalutamide arm, compared with 45.8 months in the placebo-plus-enzalutamide arm. The hazard ratio was 0.48 with a 95% confidence interval of 0.36 to 0.65 and p<0.0001. In plain terms, a hazard ratio below 1 means the treated group progressed or died at a slower rate at any given point in follow-up; 0.48 indicates roughly half the hazard of the control arm over the study period.

The biomarker requirement is the part that determines reach. HRR genes are the DNA-repair genes named in the label, and the indication is confined to patients whose mutation status is confirmed by a test the FDA has authorized for this purpose. FoundationOne CDx and FoundationOne Liquid CDx were previously cleared as companion diagnostics to identify prostate cancer patients with HRR gene alterations for treatment with this combination. The recommended talazoparib dose is 0.5 mg orally once daily alongside enzalutamide until disease progression or unacceptable toxicity, and patients must also receive a gonadotropin-releasing hormone analog or have had a bilateral orchiectomy.

The safety profile comes with explicit warnings for myelodysplastic syndrome and acute myeloid leukemia, myelosuppression and embryo-fetal toxicity. Overall survival, a secondary endpoint, was immature when the rPFS analysis was performed, so the approval record does not yet establish a survival benefit. The review ran under Project Orbis, the FDA Oncology Center of Excellence framework for concurrent submissions among international regulators, with the Australian Therapeutic Goods Administration and Health Canada participating; those applications remain under review. The FDA granted the application priority review and used the Assessment Aid, a voluntary submission from the applicant.

The practical read is that this is a precision-medicine label rather than a broad prostate cancer clearance: eligibility runs through a confirmed HRR mutation, so the treated population is set by how consistently that testing is ordered and interpreted. The rPFS result supports the combination in the population studied, while the immature survival data and the boxed-level toxicities leave the risk-benefit balance as the central question for prescribers. The signal to watch is not a forecast but a documentation trail — whether the ongoing reviews in Australia and Canada reach the same conclusion on the same evidence.